At database lock and based on 92 deaths , no difference in overall survival was noted between linsitinib and placebo ( median 323 days [ 95 % CI 256-507 ] vs 356 days [ 249-556 ] ; hazard ratio 094 [ 95 % CI 061-144 ] ; p = 077 ) .